|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
IL113812A
(en)
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
JP2003521448A
(ja)
|
1998-07-23 |
2003-07-15 |
ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
合成ペプチドおよび自己免疫疾患治療のための使用方法
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
EP1098902A4
(en)
|
1998-07-23 |
2002-07-24 |
Yeda Res & Dev |
TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
ES2408706T3
(es)
|
1998-09-25 |
2013-06-21 |
Yeda Research And Development Co., Ltd. |
Polipéptidos relacionados con el copolímero 1 para su uso como marcadores de pesos moleculares y para uso terapéutico
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
WO2000020010A1
(en)
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
AU775073C
(en)
|
1998-11-12 |
2007-05-03 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
|
|
HK1054507B
(zh)
|
2000-01-20 |
2008-10-31 |
耶达研究及发展有限公司 |
共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
|
|
US7022663B2
(en)
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
MXPA02008023A
(es)
|
2000-02-18 |
2005-06-30 |
Yeda Res & Dev |
Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
|
|
CA2411536A1
(en)
|
2000-06-05 |
2001-12-13 |
V. Wee Yong |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
DE60116467T2
(de)
|
2000-06-07 |
2006-11-02 |
Yeda Research And Development Co., Ltd. |
Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
EP1459065B1
(en)
|
2001-12-04 |
2010-07-28 |
Teva Pharmaceutical Industries, Ltd. |
Processes for the measurement of the potency of glatiramer acetate
|
|
US7351686B2
(en)
|
2001-12-06 |
2008-04-01 |
Yeda Research And Development Co. Ltd. |
Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
|
|
US7851486B2
(en)
|
2002-10-17 |
2010-12-14 |
Decode Genetics Ehf. |
Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
|
|
WO2005075022A2
(en)
|
2004-01-30 |
2005-08-18 |
Decode Genetics Ehf. |
Susceptibility gene for myocardial infraction, stroke, and paod; methods of treatment
|
|
US20080293750A1
(en)
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
|
US20060019269A1
(en)
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
|
US7507531B2
(en)
|
2002-10-17 |
2009-03-24 |
Decode Genetics Chf. |
Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
|
|
WO2004043995A2
(en)
|
2002-11-13 |
2004-05-27 |
Apotex Pharmachem Inc. |
Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
|
|
WO2004060265A2
(en)
|
2003-01-07 |
2004-07-22 |
Yeda Research And Development Co. Ltd. |
Eye-drop vaccine containing copolymer 1 for therapeutic immunization
|
|
NZ569331A
(en)
|
2003-01-21 |
2010-08-27 |
Yeda Res & Dev |
COP 1 for treatment of inflammatory bowel diseases
|
|
CA2518079A1
(en)
|
2003-03-04 |
2004-10-28 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
CA2525771A1
(en)
|
2003-05-14 |
2004-12-02 |
Teva Pharmaceutical Industries Ltd. |
Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
|
|
US20050064483A1
(en)
|
2003-08-28 |
2005-03-24 |
Baylor College Of Medicine |
Gene expression profiling technology for treatment evaluation of multiple sclerosis
|
|
CN1886506B
(zh)
|
2003-09-29 |
2012-05-30 |
中外制药株式会社 |
在nk细胞中表达的蛋白质
|
|
JP2007509981A
(ja)
|
2003-10-31 |
2007-04-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
薬物デリバリー用ナノ粒子
|
|
CA2546077C
(en)
|
2003-11-12 |
2016-07-05 |
Yeda Research And Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
|
US20100216863A1
(en)
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
|
US20050266432A1
(en)
*
|
2004-02-26 |
2005-12-01 |
Illumina, Inc. |
Haplotype markers for diagnosing susceptibility to immunological conditions
|
|
EP1778286A4
(en)
|
2004-03-03 |
2009-04-08 |
Teva Pharma |
COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
|
|
US20050266410A1
(en)
|
2004-05-19 |
2005-12-01 |
Emily Walsh |
Methods of Human Leukocyte Antigen typing by neighboring single nucleotide polymorphism haplotypes
|
|
NZ578727A
(en)
|
2004-06-25 |
2011-03-31 |
Brigham & Womens Hospital |
Proteosome compositions and methods for treating neurological disorders
|
|
CA2579038A1
(en)
|
2004-09-02 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
DK1799703T3
(da)
|
2004-09-09 |
2010-04-19 |
Teva Pharma |
Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid
|
|
HRP20160455T1
(hr)
|
2004-09-09 |
2016-07-15 |
Yeda Research And Development Co., Ltd. |
Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
|
|
DE602005016292D1
(de)
|
2004-10-29 |
2009-10-08 |
Sandoz Ag |
Verfahren zur herstellung von glatiramer
|
|
US20060172942A1
(en)
|
2005-02-02 |
2006-08-03 |
Teva Pharmaceutical Industries, Ltd. |
Process for producing polypeptide mixtures using hydrogenolysis
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
RS52867B
(sr)
|
2005-02-17 |
2013-12-31 |
Teva Pharmaceutical Industries Ltd. |
Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
|
|
US20060240463A1
(en)
|
2005-04-25 |
2006-10-26 |
Rappaport Family Institute For Research In The Medical Sciences |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
WO2007030573A2
(en)
|
2005-09-09 |
2007-03-15 |
Yeda Research And Development Co. Ltd. |
Polypeptides useful for molecular weight determinations
|
|
US20070161566A1
(en)
*
|
2006-01-11 |
2007-07-12 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
SI2046817T1
(sl)
|
2006-07-05 |
2010-04-30 |
Momenta Pharmaceuticals Inc |
Izboljšani postopek za pripravo kopolimera-1
|
|
US20080131887A1
(en)
*
|
2006-11-30 |
2008-06-05 |
Stephan Dietrich A |
Genetic Analysis Systems and Methods
|
|
US7795033B2
(en)
|
2007-03-19 |
2010-09-14 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods to predict the outcome of treatment with antidepressant medication
|
|
WO2009070298A1
(en)
|
2007-11-28 |
2009-06-04 |
Teva Pharmaceutical Industries, Ltd. |
Method of delaying the onset of clinically definite multiple sclerosis
|
|
US20090177487A1
(en)
|
2008-01-07 |
2009-07-09 |
Tera Eerkes |
Methods for Assessing Genetic Compatibility
|
|
EP2307544A4
(en)
|
2008-06-13 |
2012-09-05 |
Prognomix Inc |
GENETIC COMPONENT OF COMPLICATIONS IN TYPE 2 DIABETES
|
|
EP2310533A4
(en)
|
2008-07-04 |
2012-03-14 |
Axial Biotech Inc |
GENETIC MARKERS ASSOCIATED WITH DEGENERATIVE DISC DISEASE AND USES THEREOF
|
|
WO2010103292A2
(en)
*
|
2009-03-12 |
2010-09-16 |
Brainco Biopharma S.L. |
A genotyping tool for improving the prognostic and clinical management of ms patients
|
|
WO2010118210A1
(en)
|
2009-04-08 |
2010-10-14 |
Cedars-Sinai Medical Center |
Methods of predicting complication and surgery in crohn's disease
|
|
PT2275086E
(pt)
|
2009-07-15 |
2012-05-18 |
Teva Pharma |
Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
RS55607B1
(sr)
|
2009-08-20 |
2017-06-30 |
Yeda Research & Development Company Ltd |
Niskofrekventna terapija glatiramer acetatom
|
|
US8853378B2
(en)
|
2009-10-09 |
2014-10-07 |
Georgetown University |
Polynucleotides that home to atherosclerotic plaque
|
|
US8759302B2
(en)
*
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
EA025780B1
(ru)
|
2010-10-11 |
2017-01-30 |
Тева Фармасьютикал Индастриз Лтд. |
Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
|
|
MX2014004309A
(es)
|
2011-10-10 |
2015-07-06 |
Teva Pharma |
Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
|
|
WO2014058976A2
(en)
|
2012-10-10 |
2014-04-17 |
Teva Pharmaceutical Industries Ltd. |
Biomarkers predictive for clinical response for glatiramer acetate
|
|
EA201591187A1
(ru)
|
2012-12-21 |
2016-03-31 |
Тева Фармасьютикал Индастриз Лтд. |
Пероральная трансмукозальная доставка ацетата глатирамера
|
|
MX2015007678A
(es)
|
2012-12-21 |
2015-09-07 |
Teva Pharma |
Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.
|
|
JP2016504039A
(ja)
|
2013-01-04 |
2016-02-12 |
テバ ファーマシューティカル インダストリーズ リミティド |
グラチラマーアセテート関連医薬品の特性決定
|
|
CN105188751A
(zh)
|
2013-03-12 |
2015-12-23 |
泰华制药工业有限公司 |
利妥昔单抗诱导疗法继而醋酸格拉替雷疗法
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|